别嘌醇缓释胶囊致慢性肾衰竭患者急性加重的药物超敏反应综合征1例分析

doi:10.19803/j.1672-8629.20250024

中国药物警戒 ›› 2025, Vol. 22 ›› Issue (12): 1431-1433.
DOI: 10.19803/j.1672-8629.20250024

别嘌醇缓释胶囊致慢性肾衰竭患者急性加重的药物超敏反应综合征1例分析

其其格, 伍迪^*

云南中医药大学第一附属医院,云南省中医医院皮肤科,云南昆明 650021

收稿日期:2025-01-10 发布日期:2025-12-19
通讯作者: ^*伍迪,男,硕士,副主任医师,皮肤病防治与研究。E-mail: 66314655@qq.com
作者简介:其其格,女,本科,住院医师,皮肤病防治与研究。
基金资助:
云南省中医临床优秀人才研修项目（第一批）[云财社（2024）103号]

One Case of Acute Exacerbation of Chronic Renal Failure in a Patient with Drug Hypersensitivity Syndrome Induced by Allopurinol Sustained-Release Capsules

QI Qige, WU Di^*

Department of Dermatology, Yunnan Provincial Hospital of Traditional Chinese Medicine, Kunming Yunnan 650021, China

Received:2025-01-10 Published:2025-12-19

摘要/Abstract

摘要： 目的探讨别嘌醇缓释胶囊致药物超敏反应综合征病例, 为临床安全用药提供参考。方法分析1例成人患者使用别嘌醇缓释胶囊1月后引起药物超敏反应综合征并发慢性肾衰竭急性加重的诊治过程。结合相关文献, 分析其病例特点及药物导致不良反应的相关机制, 并梳理相关治疗措施。结果经关联性评价, 判定药物超敏反应综合征为别嘌醇所致。患者停药并予以对症治疗后, 病情稳定。结论慢性肾衰竭患者使用别嘌醇缓释胶囊可能会导致药物超敏反应综合征, 并引起肾功能急性加重, 因此用药期间应加强不良反应监测, 完善HLA-B*5801基因检测有助于降低其不良反应发生风险。

关键词: 别嘌醇, 药物超敏反应综合征, 肾衰竭, 药品不良反应, HLA-B*5801

Abstract: Objective To study one case of drug hypersensitivity syndrome caused by allopurinol sustained-release capsules so as to provide a reference for safe clinical medications. Methods The diagnosis and treatment process of an adult patient who developed drug hypersensitivity syndrome and acute exacerbation of chronic renal failure one month after using allopurinol sustained-release capsules was analyzed. Based on related literature, the characteristics of the case and the mechanisms of the drug for adverse reactions were analyzed before treatment for this patient was traced. Results Following a causality assessment, the drug hypersensitivity syndrome was attributed to allopurinol. The patient's condition was stabilized after discontinuation of medication and symptomatic treatment. Conclusion Patients with chronic renal failure who use allopurinol sustained-release capsules may develop drug hypersensitivity syndrome, potentially leading to acute deterioration of renal function. Therefore, enhanced monitoring of adverse reactions is required during treatment. HLA-B*5801 genetic testing may help reduce the risk of adverse reactions.

Key words: Allopurinol, Drug Hypersensitivity Syndrome, Renal Failure, Adverse Drug Reaction, HLA-B*5801

中图分类号:

R977
R994.11

其其格, 伍迪. 别嘌醇缓释胶囊致慢性肾衰竭患者急性加重的药物超敏反应综合征1例分析[J]. 中国药物警戒, 2025, 22(12): 1431-1433.

QI Qige, WU Di. One Case of Acute Exacerbation of Chronic Renal Failure in a Patient with Drug Hypersensitivity Syndrome Induced by Allopurinol Sustained-Release Capsules[J]. Chinese Journal of Pharmacovigilance, 2025, 22(12): 1431-1433.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://zgywjj.magtechjournal.com/CN/10.19803/j.1672-8629.20250024

https://zgywjj.magtechjournal.com/CN/Y2025/V22/I12/1431

参考文献

[1] Chinese Society of Endocrinology. Chinese Medical Association. Guideline for the Diagnosis and Management of Hyperuricemia and Gout in China(2019)[J]. Chinese Journal of Endocrinology and Metabolism(中华内分泌代谢杂志), 2020, 36(1): 1-13.
[2] SUN JM, XIA Q, YANG PP, et al.Characteristics and Evaluations of Different Diagnostic Criteria for Drug-Induced Hypersensitivity Syndrome: a Report of 75 Cases[J]. Chinese Journal of Hospital Pharmacy(中国医院药学杂志), 2024, 44(18): 2154-2158.
[3] KOLLER E, DIXIT N, LEE R, et al.A Case of Allopurinol-Induced Drug Reaction with Eosinophilia and Systemic Symptoms in a Patient with Polycystic Kidney Disease and Chronic Kidney Disease[J]. World Medical Journal, 2025, 124(2): 169-172.
[4] MĄSIOR MN, ROSTKOWSKA OM, FURMAŃCZYK-ZAWISKA A, et al. DRESS Syndrome: Renal Involvement in Two Cases-a Comprehensive Analysis and Literature Review of Improved Diagnosis and Treatment[J]. The American Journal of Case Reports, 2024, 25: e942315.
[5] SETOYAMA A, SAWADA Y.Drug-Induced Hypersensitivity Syndrome Accompanied with Acute Renal Failure with Hemodialysis: a Case Report and Literature Review[J]. Cureus, 2024, 16(1): e52335.
[6] CHEN IH, KUO MC, HWANG SJ, et al.Allopurinol-Induced Severe Hypersensitivity with Acute Renal Failure[J]. The Kaohsiung Journal of Medical Sciences, 2005, 21(5): 228-232.
[7] LIU Q, HOU W, SHEN Y, et al.Allopurinol-Induced Acute Kidney Injury and DRESS Syndrome without Eosinophilia: a Case Report[J]. Clinical Nephrology, 2021, 96(3): 188-190.
[8] DAGNON DSM, DOMINGUES SM, OLUIC S, et al.Renal Manifest-ations of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome: a Systematic Review of 71 Cases[J]. Journal of Clinical Medicine, 2023, 12(14): 4576.
[9] ESPOSITO AJ, MURPHY RC, TOUKATLY MN, et al.Acute Kidney Injury in Allopurinol-Induced DRESS Syndrome: a Case Report of Concurrent Tubulointerstitial Nephritis and Kidney-Limited Necrotizing Vasculitis[J]. Clinical Nephrology, 2017, 87(6): 316-319.
[10] ZHENG FY, WU Y, RAO YF, et al.The Role and Case Analysis of Naranjo's Scale in the Evaluation of Adverse Drug Reactions[J]. Chinese Pharmaceutical Journal(中国药学杂志), 2012, 47(8): 650-652.
[11] GONG J, XIANG Q, WHANG ZN, et al.Individualized Medication Clinical Research Analysis of Allopurinol Based on HLA-B Gene Polymorphism[J]. The Chinese Journal of Clinical Pharmacology(中国临床药理学杂志), 2022, 38(10): 1133-1136.
[12] FITZGERALD JD, DALBETH N, MIKULS T, et al.2020 American College of Rheumatology Guideline for the Management of Gout[J]. Arthritis Rheumatol, 2020, 72(6): 879-895.
[13] PAN X, XIE P, CHANG H, et al.Would Allopurinol Hypersensitivity Syndrome be a Turning Point of CKD?[J]. Immunological Journal(免疫学杂志), 2022, 38(1): 88-92.
[14] YASEEN W, AUGUSTE B, ZIPURSKY J.Allopurinol Hypersen-sitivity Syndrome[J]. Canadian Medical Association Journal, 2023, 195(13): E483.
[15] LI HH.Clinical Analysis of 65 Patients with Severe Adverse Drug Reactions[D]. Shandong: Shandong University, 2023.
[16] HAMA N, ABE R, GIBSON A, et al.Drug-Induced Hypersensitivity Syndrome(DIHS)/Drug Reaction with Eosinophilia and Systemic Symptoms(DRESS): Clinical Features and Pathogenesis[J]. The Journal of Allergy and Clinical Immunology, 2022, 10(5): 1155-1167.
[17] STIRTON H, SHEAR NH, DODIUK-GAD RP.Drug Reaction with Eosinophilia and Systemic Symptoms(DReSS)/ Drug-Induced Hypersensitivity Syndrome(DiHS)-Readdressing the DReSS[J]. Biomedicines, 2022, 10(5): 999.
[18] WEI BM, FOX LP, KAFFENBERGER BH, et al.Drug-Induced Hypersensitivity Syndrome/Drug Reaction with Eosinophilia and Systemic Symptoms. Part I. Epidemiology, Pathogenesis, Clinicopathological Features, and Prognosis[J]. Journal of the American Academy of Dermatology, 2024, 90(5): 885-908.
[19] CAO JL, XING XZ, FAN J, et al.Advances in the Pathogenesis and Prognosis of Drug-Induced Hypersensitivity Syndrome[J]. Journal of Practical Dermatology(实用皮肤病学杂志), 2024, 17(2): 93-96, 106.

别嘌醇缓释胶囊致慢性肾衰竭患者急性加重的药物超敏反应综合征1例分析

One Case of Acute Exacerbation of Chronic Renal Failure in a Patient with Drug Hypersensitivity Syndrome Induced by Allopurinol Sustained-Release Capsules

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	蒋晓峰, 杨淑婷, 白丽琴, 戚俊, 何建雄, 陈文戈, 梁祖红, 李渔, 余晓霞. 医疗机构制剂不良反应监测与评价系统构建及初步实践[J]. 中国药物警戒, 2025, 22(9): 1008-1011.
[2]	蔡杰, 韩陈媛, 江君微. 887例静脉滴注抗菌药物不良反应报告分析[J]. 中国药物警戒, 2025, 22(9): 1018-1023.
[3]	郑金凤, 吴佳妮, 林京玉, 杨雪卿. 222例口服凝血因子Xa抑制剂不良反应报告分析[J]. 中国药物警戒, 2025, 22(9): 1024-1028.
[4]	谢加力, 荀艳, 陶云松, 章圣朋. 211例新型抗肿瘤药品不良反应报告分析[J]. 中国药物警戒, 2025, 22(9): 1029-1033.
[5]	刘芹, 章嘉一, 吴烜, SOANES Nigel. 基于生成式人工智能大语言模型的文献来源药品不良反应报告自动生成平台研究与应用[J]. 中国药物警戒, 2025, 22(9): 1040-1044.
[6]	李舒悦, 邱慧颖, 吴佳琪, 高君伟. 炔雌醇环丙孕酮片致急性髓系白血病患者血小板减少期间血栓形成2例分析[J]. 中国药物警戒, 2025, 22(9): 1045-1048.
[7]	李丹, 阳雄文, 陈丹君, 付成效, 阳波. 苯扎贝特片致慢性肾病患者横纹肌溶解1例分析[J]. 中国药物警戒, 2025, 22(9): 1049-1050.
[8]	钱凤丹, 张立超, 贡翊斐. 注射用尖吻蝮蛇血凝酶致严重过敏性休克1例分析[J]. 中国药物警戒, 2025, 22(9): 1051-1053.
[9]	邵一帆, 陈秋岑, 翟惠奇, 吴伟, 褚庆民. 铝碳酸镁咀嚼片致严重过敏反应1例分析[J]. 中国药物警戒, 2025, 22(9): 1054-1056.
[10]	魏盈, 李文凤, 张宇飞, 侯欣, 杨彦伟, 樊永丽. 度伐利尤单抗注射液致脓疱型银屑病1例分析[J]. 中国药物警戒, 2025, 22(9): 1057-1060.
[11]	李明颖, 张晓霞, 孙晓黎, 赵燕, 何苗, 李艳玲, 段薇, 杨鸥. 舒更葡糖钠对腹腔镜全盆底重建术后患者恢复的影响[J]. 中国药物警戒, 2025, 22(8): 896-901.
[12]	柯秀琴, 海学武. 433例羟苯磺酸钙胶囊不良反应分析[J]. 中国药物警戒, 2025, 22(8): 924-927.
[13]	梁洁. 172例抗肿瘤药品不良反应报告分析[J]. 中国药物警戒, 2025, 22(8): 928-932.
[14]	赵牡丹, 朱明辉, 张欢, 赵远洋, 秦靖. 1例彭氏变形杆菌致糖尿病足感染的药学监护[J]. 中国药物警戒, 2025, 22(8): 937-940.
[15]	周玗洁, 黄晓婧, 陈明月, 杜鹏强, 王爱凤. 注射用头孢哌酮舒巴坦钠致重度血小板减少2例分析[J]. 中国药物警戒, 2025, 22(8): 941-943.